Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMMJ1PO)

Drug Name
SGN-CD70A Drug Info
Indication
Disease Entry ICD 11 Status REF
Non-hodgkin lymphoma 2B33.5 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMMJ1PO

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CD70 antigen (CD27-L) TTNCIE0 CD70_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
CD70 antigen (CD27-L) DTT CD70 5.138 3.35 4.621 2.907
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Non-hodgkin lymphoma
ICD Disease Classification 2B33.5
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
CD70 antigen (CD27-L) DTT CD70 1.53E-09 0.76 2.84
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02216890) Safety Study of SGN-CD70A in Cancer Patients. U.S. National Institutes of Health.
2 SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research 10/2014; 74(19 Supplement):2647-2647.